| Target Price | $8.67 |
| Price | $1.72 |
| Potential |
404.07%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Caribou Biosciences 2026 .
The average Caribou Biosciences target price is $8.67.
This is
404.07%
register free of charge
$33.60
1,853.49%
register free of charge
$4.04
134.88%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Caribou Biosciences to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Caribou Biosciences stock has an average upside potential 2026 of
404.07%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 9.99 | 9.93 |
| 71.03% | 0.58% | |
| EBITDA Margin | -1,628.53% | -1,471.56% |
| 398.99% | 9.64% | |
| Net Margin | -1,492.59% | -1,543.87% |
| 404.21% | 3.44% |
9 Analysts have issued a sales forecast Caribou Biosciences 2025 . The average Caribou Biosciences sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Caribou Biosciences EBITDA forecast 2025. The average Caribou Biosciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Caribou Biosciences Analysts have issued a net profit forecast 2025. The average Caribou Biosciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.65 | -1.64 |
| 19.57% | 0.61% | |
| P/E | negative | |
| EV/Sales | 1.36 |
10 Analysts have issued a Caribou Biosciences forecast for earnings per share. The average Caribou Biosciences EPS is
This results in the following potential growth metrics and future valuations:
Caribou Biosciences...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 26 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jan 07 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 26 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 15 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


